BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Business

  Valneva Appoints Dipal Patel as Chief Commercial Officer

  ValnevaSE, a specialty vaccine company, announced the appointment of Dipal Patel as Chief Commercial Officer and Management Board member.

  November 17, 2022

   · 

  4 min read
• Drug Development

  VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin

  VISEN Pharmaceuticals released for the first time detailed clinical data from its pivotal Phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with growth hormone deficiency in China.

  November 17, 2022

   · 

  5 min read
• BioArctic expands portfolio with alpha-synuclein Brain Transporter project

  BioArctic AB announced that the company is expanding its alpha-synuclein project portfolio.

  November 17, 2022

   · 

  3 min read
• Biotech Bay

  WiSE® Technology to Feature in Upcoming APHRS Scientific Session

  EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that the Company’s WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society Scientific Session in Singapore from the 18th to the 20th of November.

  November 17, 2022

   · 

  3 min read
• Business

  NeoDynamics Interim Report January-September 2022

  Revenues amounted to SEK 151 (339) thousand, of which SEK 73 (24) thousand capitalized costs and SEK 32 (300) thousand net sales, i.e., sales of finished products.

  November 17, 2022

   · 

  4 min read
• Business

  Lytix Biopharma third quarter 2022 results

  Lytix Biopharma, a Norwegian immune-oncology company, releases its third quarter 2022 results.

  November 17, 2022

   · 

  3 min read
• Pharm Country

  Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR’s Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

  KAHR and the Myeloma Investment Fund announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR’s lead immunotherapy drug candidate, for the treatment of multiple myeloma.

  November 17, 2022

   · 

  4 min read
• Biotech Bay

  Sonomotion Raises USD$12.4 Million in Series C Funding to Advance Development of Break Wave

  SonoMotion announces it has secured USD$12.4 million in Series C funding co-led by integrated global urology leader Advanced MedTech Holdings and SolarCity co-founder Lyndon Rive.

  November 17, 2022

   · 

  3 min read
• Drug Development

  Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential

  Immunic, Inc today reported newly available data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS).

  November 17, 2022

   · 

  11 min read
• Biotech Bay

  NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor’s Eczema Balm

  NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC ® Network With DERMAdoctor’s Eczema Balm.

  November 17, 2022

   · 

  5 min read